US Patent Issued to The Board of Trustees of the Leland Stanford Junior University, Medicenna Therapeutics on March 31 for "IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof" (Canadian, American Inventors)

ALEXANDRIA, Va., March 31 -- United States Patent no. 12,590,133, issued on March 31, was assigned to The Board of Trustees of the Leland Stanford Junior University (Stanford, Calif.) and Medicenna Therapeutics Inc. (Toronto).

"IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof" was invented by Kenan Christopher Garcia (Menlo Park, Calif.), Ignacio Moraga Gonzalez (Palo Alto, Calif.) and Fahar Merchant (Vancouver, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods and compositions are provided for enhancing anti-tumor effector immune cells with a targeting construct comprising a human IL-13 superkine and/or a human IL-4 superkine. Cytokine or additional co-stimulato...